Bone Cell Biology and Disease - Senior Research Staff - A/Prof Kong Wah Ng

A/Prof Kong Wah Ng

Principal Research Fellow
Director, Department of Endocrinology & Diabetes

Education and Professional Experience

1972     MBBS Hons (Monash)
1982     MD (Melb)
1983     FRACP
2001     FRCP (Edin)

Achievements

Editorial Board of 'Bone'
Guest Editor, Special issue: Bone Endocrinology. Molecular and Cellular Endocrinology
Member of NHMRC "Musculoskeletal' Grant Review Committee, 2008-9

Research Interests

Control of osteoblast differentiation
Osteoblast/osteoclast interactions
Metabolic bone diseases

Selected Publications

  1. Hu, Y.S., Zhou, H., Myers, D., Quinn, J.M.W., Atkins, G., Kartsogiannis, V., Ly, C., Elliott, J., Gange, C., Kostakis, P., Zannettino, A.C.W., McKinstry, W.J., Findlay, D., Gillespie, M.T., and Ng, K.W. Isolation of a human homolog of Osteoclast Inhibitory Lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res . 19 :89-99. 2004.
  2. Gange, C.T., Quinn, J.M., Zhou, H., Kartsogiannis, V., Gillespie, M.T. and Ng KW. Characterization of sugar binding by osteoclast inhibitory lectin. J Biol Chem. 279 :29043-9. 2004. • Kartsogiannis, V. and Ng, K.W. Cell lines and primary cell cultures in the study of bone cell biology (Review). Molecular and Cellular Endocrinology. 228 (1-2):79-102. 2004.
  3. Chen, X., Macica, C.M., Ng, K.W., and Broadus, A.E. Stretch-Induced PTH-Related Protein Gene Expression in osteoblasts. J Bone Min Res. 20:1454-1461. 2005 Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA. Mechanisms involved in skeletal anabolic therapies. Ann NY Acad Sci. 1068(4):458-470. 2006.
  4. Nakamura, A., Ly, C., Cipetic, M., Sims, N., Vieusseux, J., Kartsogiannis, V., Bouralexis, S., Saleh, H., Zhou, H.K., Price, J.T., Martin, T.J., Ng, K.W., Gillespie, M. T., and Quinn, J.M.W. Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Bone. 40:305-315. 2007
  5. Martin, T.J., and Ng, K.W. Perspectives. New Agents for the Treatment of Osteoporosis. IBMS BoneKEy-Osteovision. 4(11):287-289. 2007
  6. Martin T.J., Sims N.A. and Ng K.W. Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporosis International 19(8):1125-1138. 2008
  7. Kartsogiannis V, Sims NA, Quinn JM, Ly C, Cipetic M, Poulton IJ, Walker EC, Saleh H, McGregor NE, Wallace ME, Smyth MJ, Martin TJ, Zhou H, Ng KW, Gillespie MT. Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo. J. Biol. Chem. 283(45):30850-30860. 2008
  8. Milat F, Ng KW. Is Wnt signalling the final common pathway leading to bone formation? Mol Cell Endocrinol. 2009 Oct 30;310(1-2):52-62
  9. Ng KW. Future developments in osteoporosis therapy. Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):371-84.